Page 9 - Lupin

Q4FY24: Lupin, Godrej Consumer among 54 firms to report results on May 6

Q4 FY24 results today: Marico, Lupin, Gujarat Gas, Godrej Consumer Products, Indian Bank, Happiest Minds Technologies and Route Mobile will announce their fourth quarter and FY24 results on May 7

Q4 Results Preview: Lupin may see strong topline, bottomline growth

Indian pharmaceutical major Lupin is set to witness a strong financial earnings on a year-on-year (Y-o-Y) basis for the fourth quarter of the financial year 2023-24 (Q4FY23)

Lupin rises over 3% after US FDA approves Mirabegron tablets

The surge came after the United States Food and Drug Administration (US FDA) on April 20, approved the launch of Lupin's Mirabegron extended-release (ER) tablets, 25 mg, in the United States

Stocks to Watch today: Paytm, Maruti, ICICI Lombard, Lupin, PolicyBazaar

Stocks to watch on Wednesday, April 10, 2024: Seven stocks including Bandhan Bank, Exide Industries, Hindustan Copper, Vodafone Idea, India Cement, SAIL and Zee Entertainment are in F&O ban today.

Stocks to Watch: Adani Group, Torrent Power, HAL, Lupin, Railtel, KPI Green

Stocks to watch on March 18, 2024: As per PTI, the Adani group will invest more than Rs 1.2 lakh crore in FY25 across its portfolio business with a special focus on green and renewable energy

Lupin gets USFDA nod to market a generic drug to treat bacterial infections

Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat bacterial infections, in America. The company has received approval from the USFDA for Doxycycline for Injection USP, the Mumbai-based drug maker said in a statement. The company's product is the generic equivalent of Pfizer Inc's Vibramycin for injection, it added. The product will be manufactured at its Nagpur facility, Lupin said. Doxycycline for Injection USP is indicated to reduce the development of drug-resistant bacteria. As per the IQVIA MAT January 2024 data, Doxycycline for Injection USP had estimated annual sales of USD 47 million in the US market.

Lupin gets approval from USFDA for pregnancy prevention drug 'Minzoya'

Pharma major Lupin Ltd on Friday said it has received approval from the US health regulator to market its generic 'Minzoya' tablets used to prevent pregnancy. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Minzoya (Levonorgestrel and Ethinyl Estradiol tablets, and Ferrous Bisglycinate tablets) of strengths 0.1 mg/0.02 mg and 36.5 mg, Lupin said in a regulatory filing. The drug is a generic equivalent of Balcoltra (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) 0.1 mg/0.02 mg and 36.5 mg, of Avion Pharmaceuticals LLC, it added. The product will be manufactured at Lupin's Pithampur facility in India, the company said. Minzoya tablets are indicated for use by females of reproductive potential to prevent pregnancy. Levonorgestrel and Ethinyl Estradiol tablets, and Ferrous Bisglycinate tablets had estimated annual sales of USD 42 million in the US, the company said citing IQVIA MAT

Lupin soars 7%, trades at highest level since Aug 2016 on strong Q3 results

The company's profit jumped nearly 300 per cent to Rs 613 crore for the December 2023 quarter from a year ago period.

Lupin Q3 results: Net jumps 300% to Rs 613 cr on back of record sales

Nilesh Gupta, MD, Lupin Limited said, "We delivered our highest quarterly sales to date, crossed the Rs 5,000 crore mark for the first time, driven by strong growth across geographies."

Stocks to Watch today: Axis, HDFC Bk, LTFH, Airtel, Lupin, REC, JSW Energy

Stocks to watch on Wednesday, January 24, 2024: Bajaj Auto, Canara Bank, DLF, Exide, Indian Oil, Tata Steel, Tech Mahindra and TVS Motor to announce Q3 results today.

Lupin secures a tentative USFDA approval for Rivaroxaban tablets

Lupin boasts 15 manufacturing sites, 7 research centres, and a global team of more than 20,000 professionals

Bull Spread strategy for Lupin Jan expiry amid long build-up in futures

Oscillators like RSI and MFI are in rising mode and placed above 60 on the weekly chart, indicating strength in Lupin's share, said Nandish Shah

Lupin gets USFDA nod to market generic hyperuricemia treatment drug

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator to market its generic Febuxostat tablets, indicated for the chronic management of hyperuricemia in adult patients with gout. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Febuxostat tablets of strengths 40 mg and 80 mg, a generic equivalent of Uloric tablets, 40 mg and 80 mg, of Takeda Pharmaceuticals USA, Inc, Lupin said in a regulatory filing. The product will be manufactured at the company's Pithampur facility in India, it added. The company said Febuxostat tablets of strengths 40 mg and 80 mg are indicated for the chronic management of hyperuricemia (elevated serum uric acid level) in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol; who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. Febuxostat tablets had estimated annual sales of U

Lupin receives USFDA approval to market generic hypertension drug

Drug maker Lupin on Sunday said it has received approval from the US health regulator to market a generic hypertension drug in America. The company has received approval from the US Food and Drug Administration (USFDA) for Propranolol Hydrochloride extended-release capsules in multiple strengths, Lupin Ltd said in a regulatory filing. The company's product is the generic version of ANI Pharmaceuticals' Inderal LA extended-release capsules, it added. The product will be manufactured at the company's Pithampur-based manufacturing plant, the drug firm stated. Propranolol Hydrochloride extended-release capsules USP are indicated in the management of hypertension. They may be used alone or in combination with other antihypertensive agents, particularly a thiazide diuretic. As per IQVIA MAT November 2023 data, Propranolol Hydrochloride extended-release capsules had estimated annual sales of USD 71 million in the US.

Drug firm Lupin introduces smoking cessation generic product in US market

Drug firm Lupin on Wednesday said it has launched a product, used as an aid to smoking cessation treatment, in the US market. The company has launched Varenicline tablets in strengths of 0.5 mg and 1 mg, after having received approval from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a regulatory filing. The company's product is the generic equivalent of PF Prism CV's Chantix tablets, it added. It is indicated for use as an aid to smoking cessation treatment. As per the IQVIA data, Varenicline tablets had estimated annual sales of USD 412 million in the US. Shares of the company were trading 0.75 per cent up at Rs 1,406.50 apiece on the BSE.

Stocks to Watch: Delta Corp, Vedanta, KIOCL, Power Grid, M&M, IRCTC, Lupin

Stocks to Watch on January 10, 2024: The company reported 15 per cent YoY decline in Q3 consolidated revenue to Rs 231.7 crore. Net profit slumped 59 per cent to Rs 34.5 crore

Lupin gets USFDA approval to market generic medication to treat diabetes

Drug firm Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat diabetes. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Dapagliflozin and Saxagliptin tablets, the Mumbai-based drug maker said in a regulatory filing. The company's product is a generic equivalent of AstraZeneca AB's Qtern tablets, it added. This generic product will be manufactured at its Pithampur facility, the company said. Dapagliflozin and Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As per IQVIA data, Dapagliflozin and Saxagliptin tablets had estimated annual sales of USD 5 million in the US market.

US pipeline to keep pharma major Lupin's revenues on healthy trajectory

The stock of pharma major Lupin is up 14 per cent over the last eight trading sessions and is trading at Rs 1,406 a share. The gains are on expectations that margins will improve

USFDA nod to Lupin for generic Loteprednol Etabonate ophthalmic suspension

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Loteprednol Etabonate ophthalmic suspension indicated for temporary relief of seasonal allergic conjunctivitis. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Loteprednol Etabonate ophthalmic suspension, 0.2 per cent, Lupin said in a regulatory filing. It is a generic equivalent to the reference listed drug (RLD) Alrex ophthalmic suspension, 0.2 per cent of Bausch & Lomb Inc. The product will be manufactured at Lupin's Pithampur facility in India, the company added. Loteprednol Etabonate ophthalmic suspension, 0.2 per cent, is indicated for the temporary relief of signs and symptoms of seasonal allergic conjunctivitis. It had estimated annual sales of USD 29.1 million in the US market, Lupin said citing IQVIA MAT October 2023 data.

Stocks to Watch today: Paytm, Adani Wilmar, ONGC, Lupin, Kalyan Jewellers

Stocks to watch on Tuesday, December 26, 2023: Muthoot Microfin and Suraj Estate Developers to debut on the bourses today.